Full Length Research Paper
References
|
Bauduer F, Ducout L (2004). Is the assessment of von Willebrand disease prevalence an achievable challenge? The example of the French Basque Country where blood group O and factor XI deficiency are highly prevalent. J. Thromb. Haemost. 2(10):1724-6. |
|
|
Bernardo A, Ball C, Nolasco L, Moake JF, Dong JF (2004). Effects of inflammatory cytokines on the release and cleavage of the endothelial cell-derived ultralarge von Willebrand factor multimers under flow. Blood 104:100-106. |
|
|
Bowen DJ (2003). An influence of ABO blood group on the rate of proteolysis of von Willebrand factor by ADAMTS13. J. Thromb. Haemost. 1:33-40. |
|
|
Caekebeke-Peerlinck KM, Koster T, Briet E (1989) Bleeding time, blood groups and von Willebrand factor. Br. J. Haematol. 73:217-220. |
|
|
Chng WJ, Yip CY, Baliwag MB, Liu TC (2005). Differential effect of the ABO blood group on von Willebrand factor collagen binding activity and ristocetin cofactor assay. Blood Coagul. Fibrinolysis 16:75-78. |
|
|
Coppola R, Mari D, Lattuada A, Franceschi C (2003) Von Willebrand factor in Italian centenarians. Haematologica 88:39-43. |
|
|
De Cristofaro R, Peyvandi F, Palla R, Lavoretano S, Lombardi R, Merati G, Romitelli F, Di Stasio E, Mannucci PM (2005). Role of chloride ions in modulation of the interaction between von Willebrand factor and ADAMTS-13. J. Biol. Chem. 280(24):23295-23302. |
|
|
Favaloro EJ, Soltani S, McDonald J, Grezchnik E, Easton L, Favaloro JW (2005). Reassessment of ABO blood group, sex, and age on laboratory parameters used to diagnose von Willebrand disorder: potential influence on the diagnosis vs the potential association with risk of thrombosis. Am. J. Clin. Pathol. 124:910-917. |
|
|
Felmeden DC, Blann AD, Spencer CG, Beevers DG, Lip GY (2003). A comparison of flow-mediated dilatation and von Willebrand factor as markers of endothelial cell function in health and in hypertension: relationship to cardiovascular risk and effects of treatment: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial. Blood Coagul. Fibrinolysis 14:425-431. |
|
|
Gill JC, Endres-Brooks J, Bauer JP, Marks JW, Montgomery RM (1987). The effect of ABO blood group on the diagnosis of von Willebrand disease. Blood 69:1691-1695. |
|
|
Haley E, Babar N, Ritter C, Downes KA, Green D, Shurin S, Sarode R (2002). Effect of ABO blood group on the collagen-binding assay for von Willebrand factor. Am. J. Hematol. 71:229-231. |
|
|
Mannucci PM, Capoferri C, Canciani MT (2004). Plasma levels of von Willebrand factor regulate ADAMTS-13, its major cleaving protease. Br. J. Haematol. 126:213-218. |
|
|
Masayuki S, Yoshihiro F, Takayuki N, Tomomi T, Nobuhiro N, Taei M, Koti T, Masahiko K, Fumi-ichiro Y, Akira Y (1995). ABO blood group genotype and plasma von Willebrand factor in normal individuals. Vox Sang. 68:236-240. |
|
|
Miller CH, Dilley A, Richardson L, Hooper WC, Evatt BL (2001). Population differences in von Willebrand factor levels affect the diagnosis of von Willebrand disease in African-American women. Am. J. Hematol. 67:125-129. |
|
|
Miller CH, Haff E, Platt SJ, Rawlins P, Drews CD, Dilley AB, Evatt B (2003). Measurement of von Willebrand factor activity: relative effects of ABO blood type and race. J. Thromb. Haemost. 1:2191-2197. |
|
|
Nishio K, Anderson PJ, Zheng XL, Sadler JE (2004) Binding of platelet glycoprotein Ibalpha to von Willebrand factor domain A1 stimulates the cleavage of the adjacent domain A2 by ADAMTS13. Proc. Natl. Acad. Sci. USA 101:10578-10583. |
|
|
Nitu-Whalley IC, Lee CA, Griffioen A, Jenkins PV, Pasi KJ (2000). Type 1 von Willebrand disease - a clinical retrospective study of the diagnosis, the influence of the ABO blood group and the role of the bleeding history. Br. J. Haematol. 108:259-264. |
|
|
O'Donnell J, Boulton FE, Manning RA, Laffan MA (2002) Amount of H antigen expressed on circulating von Willebrand factor is modified by ABO blood group genotype and is a major determinant of plasma von Willebrand factor antigen levels. Arterioscler. Thromb. Vasc. Biol. 22:335-341. |
|
|
O'Donnell J, Laffan MA (2001). The relationship between ABO histo-blood group, factor VIII and von Willebrand factor. Transfus. Med. 11:343-351. |
|
|
O'Donnell JS, McKinnon TA, Crawley JT, Lane DA, Laffan MA (2005). Bombay phenotype is associated with reduced plasma-VWF levels and an increased susceptibility to ADAMTS13 proteolysis. Blood 106:1988-1991. |
|
|
Orstavik KH (1990). Genetics of plasma concentration of von Willebrand factor. Folia Haematol. Int. Mag. Klin. Morphol. Blutforsch. 117:527-531. |
|
|
Ray KK, Francis S, Crossman DC (2004). Measurement of plasma von Willebrand factor in acute coronary syndromes and the influence of ABO blood group status. J. Thromb. Haemost. 2:2053-2054. |
|
|
Rodeghiero F, Castaman G, Dini E (1987). Epidemiological investigation of the prevalence of von Willebrand's disease. Blood 69:454-459. |
|
|
Rumley A, Lowe GD, Sweetnam PM, Yarnell JW, Ford RP (1999). Factor VIII, von Willebrand factor and the risk of major ischaemic heart disease in the Caerphilly Heart Study. Br. J. Haematol. 105:110-116. |
|
|
Sadler JE (1994). A revised classification of von Willebrand disease. For the Subcommittee on von Willebrand Factor of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb. Haemost. 71:520-525. |
|
|
Sadler JE, Mannucci PM, Berntorp E, Bochkov N, Boulyjenkov V, Ginsburg D, Meyer D, Peake I, Rodeghiero F, Srivastava A (2000). Impact, diagnosis and treatment of von Willebrand disease. Thromb. Haemost. 84:160-174. |
|
|
Schleef M, Strobel E, Dick A, Frank J, Schramm W, Spannagl M (2005). Relationship between ABO and Secretor genotype with plasma levels of factor VIII and von Willebrand factor in thrombosis patients and control individuals. Br. J. Haematol. 128:100-107. |
|
|
Shima M, Fujimura Y, Nishiyama T, Tsujiuchi T, Narita N, Matsui T, Titani K, Katayama M, Yamamoto F, Yoshioka A (1995). ABO blood group genotype and plasma von Willebrand factor in normal individuals. Vox Sang. 68:236-240. |
|
|
Souto JC, Almasy L, Muniz-Diaz E, Soria JM, Borrell M, Bayen L, Mateo J, Madoz P, Stone W, Blangero J, Fontcuberta J (2000). Functional effects of the ABO locus polymorphism on plasma levels of von Willebrand factor, factor VIII, and activated partial thromboplastin time. Arterioscler. Thromb. Vasc. Biol. 20:2024-2028. |
|
|
Srivastava A, Rodeghiero F (2005). Epidemiology of von Willebrand disease in developing countries. Semin. Thromb. Hemost. 31:569-576. |
|
|
Studt JD, Kremer Hovinga JA, Antoine G, Hermann M, Rieger M, Scheiflinger F, Lämmle B (2005). Fatal congenital thrombotic thrombocytopenic purpura with apparent ADAMTS13 inhibitor: in vitro inhibition of ADAMTS13 activity by hemoglobin. Blood 105(2):542-4. |
|
|
Sukhu K, Poovalingam V, Mahomed R, Giangrande PL (2003). Ethnic variation in von Willebrand factor levels can influence the diagnosis of von Willebrand disease. Clin. Lab. Haematol. 25:247-249. |
|
|
Tsai HM (1996). Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion. Blood 87:4235-4244. |
|
|
Tsai HM (2003). Shear stress and von Willebrand factor in health and disease. Semin. Thromb. Hemost. 29:479-488. |
|
|
Tsai HM, Lian EC (1998). Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N. Engl. J. Med. 339:1585-1594. |
|
|
Ukaejiofo EO, Isaac-Shodeye WA, Adigun ES, Ipadeola A (1979) Normal haematological values for adult Nigerians. Niger. Med. J. 9:117-119. |
|
|
Ulrich B, Rudiger S, Peter F, Katharina H-B, Judith D, &Zaverio MR (1993) Elevated Platelet Count as a Cause of Abnormal von Willebrand Factor Multimer Distribution in Plasma. Blood 1749-1757. |
|
|
van der Meer IM, Brouwers GJ, Bulk S, Leebeek FW, van der Kuip DA, Hofman A, Witteman JC, Gomez Garcia EB (2004). Genetic variability of von Willebrand factor and risk of coronary heart disease: the Rotterdam Study. Br. J. Haematol. 124:343-347. |
|
Copyright © 2025 Author(s) retain the copyright of this article.
This article is published under the terms of the Creative Commons Attribution License 4.0
